This webinar will touch upon why the older model of funding academic research and building your career as a professor through NIH’s RO1-type general grants, supplementing with pharmaceutical grants during brief hiatus periods, is no longer a viable option for most.
This model leads to frustration and to seeking new career options. It is particularly true when the focus is basic research.
We have found success in an “entrepreneurial model” that takes advantage of changes that are part of our world globalization and the increased medical needs of our society. Along with a decrease in standard, basic research funding from NIH has come an increase in translational (i.e. bench to bedside) funding worldwide.
This shift is seen both academic directed grants as well as government based (including NIH) small business innovative grants (SBIR) used to develop a technology. Successful adaption requires forming and advancing multiple collaborations with others in academics as well as industry where joint interests exist, and in sharing both the responsibilities as well as the rewards.
Built-in is the potential of seeing your work advance to a new prevention or treatment option for patients. Further gains come from understanding how business integrates with medicine and in having an impact on how this new system evolves into the future.
Dr. Bruce Riser is an R & D Pharmaceutical Leader / Biotech Founder, CEO/CSO and an expert in cardio-renal and fibrotic disease. After a career in pharmaceutical R&D and research in academic medicine, Dr. Riser founded BLR Bio. It's mission is to discover and develop first-in-class technology to diagnose, prevent and treat chronic disease and cancer, the two largest killers in the Western world. Its technology platform focuses on fibrosis in cardio-renal and liver disease, skin scarring and complications of diabetes, as well as cancer. Dr Riser has published more than 70 peer reviewed research articles and book chapters in the fields of cardiology, dermatology, nephrology, cancer, immunology, infectious disease, dialysis therapy, drug development, and diagnostics. He is the inventor of 20 plus issued patents.